SMMT Q2 2025 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$37,000

Operating Income

-$568M

Net Income

-$566M

EPS (Diluted)

$-0.76

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$67M

Stock-Based Comp.

$479M

Balance Sheet

Total Assets

$324M

Total Liabilities

$65M

Stockholders' Equity

$259M

Cash & Equivalents

$298M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$37,000	-$20,000	-85.0%
Operating Income	-$568M	-$60M	-853.5%
Net Income	-$566M	-$60M	-836.8%